WEBULL
WebtradeDownload

Is Bausch + Lomb (BLCO) Undervalued After Its CEO Change?

Simply Wall St · 1d ago

Bausch + Lomb (BLCO) has just undergone a leadership shakeup, with CEO Brent Saunders departing and board chair Thomas J. Appio stepping in as interim chief executive, drawing fresh investor attention to the stock.

Recent trading shows that momentum around Bausch + Lomb has cooled, with the 7 day share price return down 7.5% and the 30 day move lower by 8.76%, even though the 1 year total shareholder return of 7.15% is still positive. The leadership change and October update on BL1243 for dry age related macular degeneration sit against this backdrop as investors reassess both growth prospects and execution risk while the stock trades at US$16.04 after a 1 day share price gain of 1.45%.

Spot opportunities around Bausch + Lomb's leadership and pipeline reset by scanning a hand picked 20 high quality undiscovered gems featuring companies with similarly strong fundamentals that may not yet be fully appreciated by the market.

The recent pullback, alongside a still positive 1-year return, leaves Bausch + Lomb at US$16.04. Are investors reacting to the business reset, or simply marking down sentiment ahead of the next valuation check?

Most Popular Narrative: 59% Undervalued

The dominant valuation story around Bausch + Lomb pegs fair value at $39.23, far above the recent $16.04 close, which puts a spotlight on how investors weigh governance noise against long term cash flow potential.

The Silence After the AGM: A Retail Investor’s Timeline, Findings, and Opinion on an Unprecedented Governance Failure

For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, not industry standard, and not aligned with the obligations of a publicly traded company.

See why 5 investors see Bausch + Lomb as 59% undervalued.

Result: Fair Value of $39.23 (UNDERVALUED)

Still, the AGM disclosure gap and current net loss of US$171 million could quickly challenge any Bausch + Lomb undervaluation thesis if investor confidence weakens further.

Find out about the key risks to this Bausch + Lomb narrative.

Next Steps

Sentiment around Bausch + Lomb is clearly split, with governance questions on one side and long term potential on the other. Move quickly, drill into the underlying numbers, and weigh both the 1 or more risks and the 1 or more rewards captured in 4 key rewards and 1 important warning sign.

Looking for more Bausch + Lomb style ideas?

If Bausch + Lomb has you thinking harder about valuation, diversification and risk, do not stop at a single ticker. Broaden your watchlist now before others move first using the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.